
valu
price data provid thomson reuter
number may add due round
great start
argx kick continu clinic execut lead pipeline-in-a-product
candid efgartigimod report posit clinic data pemphigu vulgari pv
acceler guidanc top-line ph adapt readout gener
myasthenia gravi gmg pv updat data
efficacy-evalu pt treat iv efgartigimod mg/kg
highlight diseas control rate achiev median
day diseas control defin show sign exist lesion heal
absenc new lesion format furthermor clinic remiss
cr rate achiev within wk report
pt receiv optim dose regimen note biweekli
efgartigimod administr combin oral prednison mg/
kg safeti toler profil also report favor view
pv updat show better-than-expect competit diseas control
remiss rate meaning sampl size pv pt consequ enhanc
convict efgartigimod success indic view larg
underappreci among investor focu understand place
attract later-stag mg itp opportun
refer note efgartigimod data stack favor
principia cover oral btk inhibitor weve
long view efgartigimod primari competit pv among clinical-stag
candid rituxan like offer signific competit current
market also watch alexion outperform laura
chico fcrn antagonist shown earli poc small ph
trial lag develop
data part ph believ studi consist
pt treat optim dose regimen mg qd intra-
patient escal bid longer treatment durat month
month part includ cr rate diseas control rate
wk wk pt achiev pdai score
posit note efgartigimod shown numer greater diseas
control remiss rate notabl rapid onset howev given
differ trial design lack report color subgroup dynam
 patient breakdown baselin pdai score diseas sever use
amount concomit steroid dose regimen reliabl ph data
comparison difficult make time look forward
upcom present detail ph result product candid
expect medic confer later year look gain better
sens drug potenti competit posit
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
nevertheless given current dataset increas expect peak
penetr efgartigimod pv us/eu market
larg respons increas pt
moreov given encourag emerg dataset compani elect
advanc candid pivot trial efgartigimod argx anticip initi
registr trial recent initi ph pegasu trial
evalu background taper corticosteroid placebo
pt adult newli diagnos relaps moderate-to-sever pemphigu roughli
total address pemphigu market primari endpoint
studi proport pt achiev durabl cr defin proport
pt achiev state lesion heal new lesion
appear wk treatment studi also look cumul steroid
use time cr believ import metric potenti competit
differenti look argx efgartigimod trial greatli influenc
beyond pemphigu argx also updat guidanc outlook compani
gmg expect top-line result push bla submiss
guid model commerci launch top-line adapt data remain
signific catalyst argx share although fda feedback potenti bridg
strategi enhanz efgartigimod gmg also meaning updat given
signific commerci advantag believ sc formul promis program
efgartigimod chronic immun demyelin polyneuropathi cidp argx note
recent initi ph adher trial enhanz formul
cidp symposium note discuss cidp adher enhanz
efgartigimod immun thrombocytopenia itp efgartigimod current
evalu ph advanc trial mg/kg iv formul target
induct mainten treatment argx also anticip initi
advanc sc trial evalu mg/kg iv efgartigimod induct
therapi follow sc fix dose mainten set argx
anticip advanc enhanz formul itp allow greater flexibl
price dynam argx also expect initi addit small confirmatori iv trial
part registr itp program
addit label expans effort efgartigimod argx anticip announc
efgartigimod fifth target indic
janssen-partn cusatuzumab acut myeloid leukemia aml data updat
cusatuzumab develop program expect recal argx
janssen continu enrol pt ph culmin trial cusatuzumab
azacitidin newly-diagnos aml pt unfit intens chemo well ph
combin trial cusatuzumab venetoclax azacitidin variou aml
subpopul set addit trial also expect initi
includ addit combin trial aml random ph trial higher-risk
earlier-stag pipelin effort beyond lead candid efgartigimod
cusatuzumab argx plan initi ph healthi volunt trial
mab iv enhanze-sc follow initi ph
trial multifoc motor neuropathi mmn later year lead optim work
mab airway inflamm disord also continu
new product candid also expect announc
year prior note
reiter rate outperform increas pt sum-
of-part valuat base multipl efgartigimod sale mg discount back
itp cidp itp discount back respect plu
multipl argx share us cusatuzumab sale multipl ex-u royalti
discount back chang pt model result primarili increas
model competit posit efgartigimod pv increas expect peak
penetr us/eu updat valuat tabl financi
sum-of-part base multipl ww efgartigimod sale mg/itp/pv/cidp discount plu mult
us/ex-u cusatuzumab sales/royalti aml discount
risk attain price rate
risk attain price target rate includ clinic regulatori commerci failur efgartigimod
david nierengarten jeffrey la rosa matthew barcu certifi view express report accur reflect
person opinion directli indirectli receiv compens payment connect
specif recommend view contain report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
januari
januari
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
ws make market secur argen-x inc
ws co-manag public offer secur argen-x within last month
ws provid argen-x invest bank servic within last month
ws expect receiv compens invest bank servic argen-x within next month
power bluematrix
argen-x rate histori
inc rate histori
power bluematrix
wedbush disclosur price chart updat within first fifteen day new calendar quarter per finra regul price
